Trihexyphenidyl

Parkinson's disease is a common degenerative disease of the nervous system in middle-aged and elderly people. The prevalence rate among people over 65 years old in China reaches 1.7%, and patients are often troubled by symptoms such as resting tremor and muscle rigidity, which seriously affect the quality of life. Trihexyphenidyl is a central anticholinergic drug. It selectively blocks the cholinergic neural pathway in the striatum and restores the balance between dopamine and acetylcholine in the brain, thereby improving the extrapyramidal symptoms of Parkinson's disease. It can also be used for the treatment of drug-induced extrapyramidal disorders, and is one of the core medications for patients with mild symptoms, those who cannot tolerate levodopa, or young patients with prominent tremor. Meanwhile, it is often used in clinical psychiatry as an antagonist for adverse reactions of antipsychotic drugs, covering two clinical scenarios of geriatric neurology and psychiatry.

At present, the market size of anti-Parkinson's disease drugs in China has exceeded 4 billion yuan, with an annual compound growth rate maintained at around 8%, among which anticholinergic drugs, as basic medications, account for about 12%. Due to its long marketing time and mature clinical pathway, trihexyphenidyl has become a commonly used variety in primary medical institutions. The domestic market is mainly supplied by generic drugs. In the seventh batch of national centralized drug procurement in 2022, the winning bid price of trihexyphenidyl hydrochloride tablets dropped to less than 0.1 yuan per tablet, which further improved clinical accessibility, and the drug consumption in primary terminals has increased by 23% in the past three years.

The original research enterprise of trihexyphenidyl is Pfizer, with the trade name Artane. The core compound patent expired globally in the 1970s. At present, the mainstream dosage form is oral tablets of 2mg specification. The original research product has been included in the FDA Reference Listed Drug Catalog, and the original research preparation has not been imported into China. Domestically, a number of enterprises have obtained A-status registration numbers for trihexyphenidyl hydrochloride API, and there are more than 20 domestic approval documents for trihexyphenidyl hydrochloride tablets, all of which have passed or are deemed to have passed the consistency evaluation. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of trihexyphenidyl impurity reference standards. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can fully meet the reference standard use requirements of different stages such as API research and development, quality research, consistency evaluation, etc., helping enterprises efficiently promote the implementation of relevant projects.